Good response to neoadjuvant chemoradiotherapy predicts good oncological outcome in locally advanced rectal cancer.

Good response to neoadjuvant chemoradiotherapy predicts good oncological outcome in locally advanced rectal cancer.
复制标题

对新辅助放化疗的良好反应预示着局部晚期直肠癌的良好肿瘤学结果

DOI:
10.21037/tcr.2019.01.17
复制
发表时间:
2019-03
影响因子:
0.9
通讯作者:
Sun X
Sun X
中科院分区:
医学4区
文献类型:
--
作者:
Zhang C;Xu L;Qin Q;Liu J;Tang X;Jiang N;Zhang Z;Li F;Cheng H;Chen J;Sun X

文献摘要

参考文献

被引文献

相似文献

背景术前同步长疗程放化疗(CRT)后,病理完全缓解(pCR)的肿瘤学结局较好,但中度缓解(TRG 1)能否转化为良好的临床结局尚不确定。方法132例局部晚期直肠癌患者行新辅助放化疗后行根治术。回顾性分析其临床病理特征和临床资料。进行临床病理参数与病理反应之间的关联,并进行病理反应与生存之间的关联的多变量分析。结果中位随访时间为21.5个月,性别是唯一与pCR相关的因素(TRG 0),而双药化疗方案与良好反应的可能性较低相关(TRG 0 -1)。多因素校正后,良好反应(TGR 0 -1)与总生存期(OS)和无病生存期(DFS)仍显著相关。与TRG 2 -3相比,TRG 1与更好的DFS相关。结论CRT术后疗效良好的患者(TRG 0 -1)局部和远端控制效果良好,尤其是非pCR患者(TRG 1)预后更好。
Background After pre-operative concurrent long course chemoradiotherapy (CRT), pathologic complete response (pCR) has been reported with better oncologic outcomes in many articles, whether a moderate response (TRG1) can translate into good clinical outcome remains uncertain. Methods A total of 132 locally advanced rectal cancer patients with neoadjuvant chemoradiotherapy followed by radical surgery were recruited. Their clinicopathologic characteristics and clinical records were retrospectively reviewed. The association between clinicopathologic parameters and pathological response was conducted, and the multivariable analysis of the association between pathologic response and survival was performed. Results With a median follow-up of 21.5 months, gender was the only factor associated with pCR (TRG0), while dual-agent chemotherapy regimen was linked with a lower likelihood of good response (TRG0-1). Good response (TGR0-1) remained significant associated with overall survival (OS) and disease-free survival (DFS) after multivariate adjustment. TRG1 was linked with better DFS compared with TRG2-3. Conclusions Patients with post-CRT good response (TRG0-1) demonstrate an excellent local and remote control, especially with those non-pCR patients (TRG1) getting better outcomes.
DOI: 10.1007/dcr.0b013e31820eeb37
发表时间: 2011-07-01
影响因子: 3.9
作者:
Fleming, Fergal J.;Pahlman, Lars;Monson, John R. T.
通讯作者: Monson, John R. T.
DOI: 10.1016/j.ijrobp.2010.02.025
发表时间: 2011-06-01
影响因子: 7
作者:
Moureau-Zabotto, Laurence;Farnault, Bertrand;Salem, Naji
通讯作者: Salem, Naji
DOI: 10.1016/s1470-2045(15)00159-x
发表时间: 2015-08-01
期刊: LANCET ONCOLOGY
影响因子: 51.1
作者:
Roedel, Claus;Graeven, Ullrich;Seipelt, G.
通讯作者: Seipelt, G.
DOI: 10.1056/nejmoa040694
发表时间: 2004-10-21
影响因子: 158.5
作者:
Sauer, R;Becker, H;Raab, R
通讯作者: Raab, R
DOI: 10.1016/j.amjsurg.2006.08.061
发表时间: 2006-12-01
影响因子: 3
作者:
Tran, Cam-Ly;Udani, Sejal;Stamos, Michael J.
通讯作者: Stamos, Michael J.